Kornimate/medical-research-clean huggingface dataset:
urodynamic studies prior to surgery for stress urinary incontinence

Conditions: Urodynamic Studies

Summary: this retrospective descriptive study is to determine what proportion of cincinnati urogynecology associates patients who underwent surgical management for stress urinary incontinence (sui) would qualify for a basic office exam (boe) alone, using the inclusion and exclusion criteria of the value of urodynamic evaluation (value) trial, and thus could have potentially had urodynamic studies (uds) omitted from their preoperative workup.

urodynamic studies (uds) are an assessment tool used to evaluate physiologic variables during bladder filling, bladder storage, and bladder emptying. they are commonly performed as part of the routine preoperative evaluation of women with symptoms of sui. however, uds are costly, with payments allowed by medicare quoted at greater than $500, time consuming, uncomfortable, and have been shown to increase the risk of urinary tract infection. but most concerning is the fact that uds have not been shown to improve surgical outcomes. in 2012, the value of urodynamic evaluation (value) trial evaluated 630 women who underwent a basic office exam (boe) or boe plus uds, and concluded that for women with uncomplicated, demonstrable sui a boe alone was not inferior to evaluation with uds for outcomes at 1 year. this recent publication has resulted in urogynecology practices across the country evaluating their own standard of care when it comes to preoperative evaluation of sui. cincinnati urogynecology associates, trihealth inc. standard practice is to perform uds on all patients undergoing surgery for sui. the providers of cincinnati urogynecology associates, trihealth inc. would be remiss if the providers did not follow this trend and evaluate their own personal practice of preoperative uds in patients presenting with sui.

Eligibility criteria:
inclusion criteria: * all women 18 years of age or older * underwent surgery for sui performed by a physician at cincinnati urogynecology associates, trihealth inc. between january 2015 and december 2015 exclusion criteria: * age \< 18 years old * concomitant surgery for anterior or apical pelvic organ prolapse
endoscopic third ventriculostomy vs. ventriculoperitoneal shunt in idiopathic normal pressure hydrocephalus (endovest)

Conditions: Idiopathic Normal Pressure Hydrocephalus (INPH)

Summary: the aim of this single-center, two-arm, open-labeled, randomized controlled clinical study is to compare two surgical interventions, endoscopic third ventriculostomy and ventriculoperitoneal shunt, in treating idiopathic normal pressure hydrocephalus in terms of clinical improvement.

idiopathic normal pressure hydrocephalus (inph) primarily affects elderly individuals, with prevalence rates of approximately 1.4% among those over 65 years and 5.9% among those over 80 years old. it is characterized by fluid buildup in the brain with normal cerebrospinal fluid pressure and is unique among neurodegenerative disorders in its potential for successful treatment. common symptoms include difficulty walking, urinary incontinence, and cognitive decline, which significantly impact quality of life. the standard treatment involves inserting a ventriculoperitoneal shunt (vps) to drain cerebrospinal fluid, achieving a 75% success rate in improving symptoms. however, vps has a drawback: a high rate of revision surgery (approximately 18% during follow-up). an alternative treatment is endoscopic third ventriculostomy (etv), which avoids placing foreign materials and thus eliminates risks associated with shunt malfunction and infections. etv is an established neuroendoscopic procedure mainly used to treat non-communicating hydrocephalus, typically due to aqueduct stenosis. this study aims to compare etv and vps for the treatment of inph to investigate whether etv leads to fewer complications while achieving a comparable rate of postoperative symptom improvement.

Eligibility criteria:
inclusion criteria: * \>40 years of age * symptom duration ≥3 months, \<24 months * no antecedent head trauma, ich, meningitis, or other cause of secondary hydrocephalus * must show gait/balance disturbance, plus cognition impairment and/or urinary dysfunction. * ventricular enlargement (evans index \> 0.3) not attributable to cerebral atrophy or congenital enlargement * no macroscopic obstruction to cerebrospinal fluid (csf) flow spinal tap-test * opening pressure (on lateral decubitus): \<24cmh2o * clinical improvement in at least one of the main symptoms after 40-50ml withdrawal of csf exclusion criteria: * ≤40 years of age * no informed consent * other neurologic, psychiatric or general medical condition which is sufficient to explain the presenting symptoms. * previous cranial neurosurgical interventions * other associated dementia syndromes * incapacity to walk * pregnancy and breastfeeding women

Keywords: surgical treatment neurosurgery endoscopic third ventriculostomy (etv) ventriculoperitoneal shunt (vps)
time-restricted enteral nutrition versus continuous enteral nutrition in patients with severe stroke

Conditions: Stroke; Time Restricted Feeding

Summary: in patients with severe stroke whose gcs score is ≤12 points or nihss score is ≥11 points, to evaluate whether time-restricted enteral nutrition can improve the incidence of poor 90-day prognosis (mrs ≥3 points) compared with continuous enteral nutrition.

control the daily enteral nutrition time to 8-12 hours, enteral nutrition start time: 06:00 \~ 08:00, end time: 16:00 \~ 18:00. enteral nutrition lasts until the patient discontinues enteral nutrition, the patient dies, the patient is transferred from the icu, or enteral nutrition is used until 28 days, whichever event occurs first. on the first day of enrollment: the patient is given 1/3 of the estimated energy and 1.2-1.5g/kg/d of protein through enteral nutrition; on the second day of enrollment: the patient is given 1/2 of the estimated energy and 1.2-1.5g/kg/d of protein through enteral nutrition; enrollment 3 - end of intervention: the patient is given 100% of the estimated energy through enteral nutrition, which can fluctuate between 70% and 100% of the estimated energy, and the protein is 1.2-1.5g/kg/d. the control group was continuous enteral nutrition (24 hours), which lasted until the patient stopped taking enteral nutrition, the patient died, the patient was transferred from the icu, or enteral nutrition was used until 28 days, whichever event occurred first. on the first day of enrollment: the patient is given 1/3 of the estimated energy and 1.2-1.5g/kg/d of protein through enteral nutrition; on the second day of enrollment: the patient is given 1/2 of the estimated energy and 1.2-1.5g/kg/d of protein through enteral nutrition; enrollment 3 - end of intervention: the patient is given 100% of the estimated energy through enteral nutrition, which can fluctuate between 70% and 100% of the estimated energy, and the protein is 1.2-1.5g/kg/d.

Eligibility criteria:
inclusion criteria: * age ≥18 years old and \<80 years old; * cerebral parenchymal hemorrhage or cerebral infarction within 72 hours of onset; * gcs score ≤12 points or nihss score ≥11 points on admission, * enteral nutrition is planned, and the estimated enteral nutrition treatment time is ≥7 days; * signed informed consent form. exclusion criteria: * complete parenteral nutrition is required due to contraindications to enteral nutrition; * after gastrectomy or intestinal resection; * enteral nutrition treatment has been performed for \>12 hours; * accompanying diseases: a. advanced cancer; b. severe cardiac insufficiency \[ejection fraction ≤ 50%\]; c. severe liver failure \[child pugh score ≥ 7\]; d. severe renal failure \[glomerular filtration\] rate ≤ 30 ml/min or serum creatinine ≥ 4 mg/dl\]) * have a history of mental illness or mrs ≥ 3 points; * the patient's doctor or nutritional therapist believes that the plan is not in the best interest of the patient; * during the patient's admission, death is inevitable, and there are underlying diseases that result in a survival time of \<90 days; * the patient participates in another clinical study.
comparsion between intravenous infusion of ketofol and inhalational anasthetics in abdominal cancer surgeries for post operative analgesia

Conditions: Abdominal Cancer

Summary: ( post operative pain between intravenous infusion ketofol and standard inhalational general anesthesia in abdominal cancer surgeries )

ketofol, which is a combination of ketamine and propofol, has been increasingly used because the advantages and disadvantages of propofol and ketamine complement each other and increase their effectiveness. recently, the use of a combination of ketamine and propofol (ketofol) as a sedative has been attracting attention in various clinical fields. theoretically, the combination of ketamine and propofol can reduce the dose of each drug and compensate for the disadvantages of the other through the antagonistic characteristics of both drugs, resulting in beneficial results for successful sedation . most of the time propofol and ketamine have been used as an induction agent in adult surgical patients but propofol may cause cardiorespiratory depression while ketamine increases heart rate and arterial blood pressure. on the other hand, the clinical effects of propofol and ketamine seem to be complementary. ketofol is most commonly used for procedural sedation hence exploring its effectiveness for induction will be paramount for the clinical care of surgical patients inhalation anesthetics (nitrous oxide, halothane, isoflurane, desflurane, sevoflurane, most commonly used agents in practice today) are used for induction and maintenance of general anesthesia in the operating room. the volatile anesthetics (halothane, isoflurane, desflurane, and sevoflurane) are liquids at room temperature and require the use of vaporizers for inhalational administration. nitrous oxide is already under normal conditions of temperature and pressure. all inhalational anesthetics provide amnesia and immobility, except for nitrous oxide, which also provides analgesia. inhaled anesthetics are commonly used in combination with iv anesthetic agents. these agents have fda approval for use as a general anesthetic and sedation agent in the operating room. inhaled anesthetic agents have also had use in the intensive care unit, but this is not an fda-approved indication. the primary applications of inhaled anesthetic agents in the icu are sedation, refractory bronchospasm, and control of status epilepticus unresponsive to anticonvulsant medications.

Eligibility criteria:
inclusion criteria: * a. inclusion criteria: 1. age group 18 - 60 years old. 2. both gender 3. asa 1and 2 exclusion criteria: * a. inclusion criteria: 1. age group 18 - 60 years old. 2. both gender 3. asa 1and 2 b. exclusion criteria: 1. patient refusal, 2. history of cardiac or respiratory disease, psychological disorders, 3. high risk of regurgitation or aspiration based on a history of diabetes, hiatus hernia, gastroesophageal reflux, and obesity, 4. neck pathology, 5. predicted difficult airway (history of difficult airway, mouth opening
the evaluation of piezo and endonasal osteotomy methods on postoperative healing process in septorhinoplasty

Conditions: Nasal Deformity, Acquired; Septum; Deviation, Congenital

Summary: the goal of this observational study is to compare the effect of piezo and endonasal osteotomy techniques on the healing process of patients undergoing septorhinoplasty surgery. the main question\[s\] it aims to answer are: * in which osteotomy technique the edema is lesser? * which osteotomy technique is better for thick vs thin skinned patients ? in which osteotomy technique the healing process is faster? participants will be asked to have an ultrasonic measurement of the nasal dorsum preoperatively and at the first, third and tenth months postoperatively. researchers will compare the thick and thin skinned patients to detect which osteotomy technique is superior in the healing process ( lesser edema and faster healing due to skin thickness measurements)

the goal of this observational study is to compare the effect of piezo and endonasal osteotomy techniques on the healing process of patients undergoing septorhinoplasty surgery. the main question\[s\] it aims to answer are: * in which osteotomy technique the edema is lesser? * which osteotomy technique is better for thick vs thin skinned patients ? in which osteotomy technique the healing process is faster? 18-65 years old males or females with nasal septum and/or nasal pyramid deviation and external nasal deformities who are willing to undergo open rhinoplasty procedure will be included in the study. patients who have a history of previous rhinoplasty/septorhinoplasty procedure, abnormal coagulation parameters (prothrombin time, partial thromboplastin time, bleeding/coagulation time), use of anticoagulant drugs, chronic / inflammatory skin disease and/or chronic skin allergies, systemic diseases (hypertension, diabetes mellitus, bronchial asthma), nasal beautification procedures such as dermal fillings, using oral and/or topical (nasal skin) corticosteroids in three months preoperatively will be excluded. participants will be asked to have an ultrasonic measurement of the nasal dorsum preoperatively and at the first, third and tenth months postoperatively. researchers will compare the thick and thin skinned patients to detect which osteotomy technique is superior in the healing process ( lesser edema and faster healing due to skin thickness measurements).

Eligibility criteria:
inclusion criteria: * nasal respiratory dysfunction with the deviation of nasal septum and/or the nasal pyramid exclusion criteria: * previous rhinoplasty/septorhinoplasty procedure * patients with abnormal coagulation parameters (prothrombin time, partial thromboplastin time, bleeding/coagulation time) * use of anticoagulant drugs * chronic / inflammatory skin disease and/or chronic skin allergies * presence of systemic diseases (hypertension, diabetes mellitus, bronchial asthma) * nasal beautification procedures such as dermal fillings * use of oral and/or topical (nasal skin) corticosteroids in three months preoperatively

Keywords: rhinoplasty edema piezosurgery osteotomy
study to evaluate the safety and effectiveness of zostavax™ in subjects 50 - 59 years of age (v211-022)

Conditions: Shingles

Summary: this study will look at how well zostavax™ works in preventing shingles in participants ages 50-59 years old.


Eligibility criteria:
inclusion criteria: * must be between 50 - 59 years of age * no fever on day of vaccination * females of reproductive potential must be willing to use acceptable form of birth control exclusion criteria: * have received chicken pox or shingles vaccine * have already had shingles * have recently had another vaccination * pregnant or breast feeding. have participated in another research study in the last 30 days * you are taking certain antiviral drugs * history of allergic reaction to any vaccine component, including gelatin or neomycin
oral contraceptive during menopausal transition

Conditions: Perimenopause

Summary: muscle or joint pain is one of the most common symptoms during menopausal transition. as this could be severe enough to affect social and daily life and to reduce quality of life, attentions should be paid about this. although understanding of muscle or joint pain related to menopause is still insufficient, estrogen can play an important role. previous studies have shown that estrogen protects cartilage in both animals and humans. however, perimenopause is different from postmenopause, in the point that estrogen is still secreted with a great fluctuation. until now, no study has been performed to evaluate the effects of oral contraceptive on muscle or joint pain in women during menopausal transition. moreover, since menopausal symptoms vary according to ethnicity and culture, a study in korean population is necessary. therefore, this randomized controlled trial was designed to evaluate the effects of oral contraceptive on muscle or joint pain in women during menopausal transition, compared to nsaid (non-steroidal anti-inflammatory drug).


Eligibility criteria:
inclusion criteria: * perimenopausal women aged 45 or more * women who have multiple joint or muscle pain for at least 3 months (at least two sites out of upper and lower extremities or axial) exclusion criteria: * rheumatoid arthritis, ankylosing spondylitis, rheumatic polymyalgia, inflammatory myopathy * pregnancy * history of hysterectomy or bilateral oophorectomy * vasomotor symptoms * history of surgery of musculoskeletal system * history of cancer * abnormalities of thyroid function * focal neurologic deficit * smoking within 1 year * uncontrolled hypertension * coronary heart disease * diabetes mellitus * stoke * active thromboembolism * undiagnosed vaginal bleeding * acute hepatic dysfunction * gastrointestinal ulcer * severe renal dysfunction * hypersensitivity to drugs * current hormone user or past users within 3 months
vascular affection in behcet disease

Conditions: Behcet Disease and Vascular Involvement

Summary: to measure the level of serum elafin in patients with behcet disease and to assess the correlation between serum elafin and vascular affection and their relation with disease activity

behcet disease is a chronic multi systemic inflammatory disease characterized by recurrent oral and genital ulcers and multiple systemic affection . elafin is a serine protease inhibitor produced mainly by epithelial cells . previous studies documented the role of serum elafin in pathogenesis of behcet disease.vascular complications may be one if the earliest manifestation leading to the diagnosis of behcet disease.

Eligibility criteria:
inclusion criteria: * patients diagnosed as behcet disease age (20-45) exclusion criteria: * age \ 45 other autoimmune diseases risk factors (ischemic heart disease, diabetes) chronic conditions (malignancy, chronic kidney disease)
the effectiveness of the manual therapy on infant colic (mt-if)

Conditions: Infant Colic

Summary: the main goal of this study is to get to know if applying manual therapy will reduce the infant colic symptoms for to improve quality of life of babies and parents.

background: infant colic is one of the most common disorders in the first year of baby´s life. it is estimated to affect between 10 to 40 % of healthy born children in their first year of life. to determine the effectiveness of a protocol manual therapy in the treatment of colic, using the infant colic severity questionnaire, we analyzed two intervention groups: experimental in which children received the protocol manual therapy and counseling to parents and the control group, in which parents received advice only. objectives: to assess the effectiveness of visceral manual therapy to improve the symptoms on infant colic.

Eligibility criteria:
inclusion criteria: * infants with medical diagnostic of colic following wessel criteria. exclusion criteria: * infant's parents without full capacity to answer the survey questions, such as the existence of intellectual disability. * babies with neurological disorders such epilepsy, meningitis, encephalitis, cerebral palsy, spina bifida, hydrocephalus, encephalopathy, arnold chiari malformation, syringomyelia and huntington's disease. * babies with digestive disorders, such crohn's disease, irritable bowel syndrome, peritonitis, intestinal malabsorption, hepatitis, diverticular bowel disease, esophagitis, intussusception and ulcerative colitis. * babies with congenital diseases such angelmen syndrome, down syndrome, cystic fibrosis, haemophilia, klinefelter syndrome, neurofibromatosis, patau syndrome and tay sachs syndrome. * babies with traumatology - orthopedic pathologies such idiopathic scoliosis, spondylolisthesis, perthes disease, meyer dysplasia, marfan syndrome, morquio syndrome and congenital hip dislocation. * babies with dermatological diseases such atopic dermatitis, staphylococcal scalded skin syndrome, psoriasis, urticaria and disorders of skin pigmentation. * babies who are subjected to drug treatments that are not specific to the treatment of colic.

Keywords: infant colic manual therapy effectiveness
multicenter real-life observational study switched aflibercept or ranibizumab to faricimab in patients with amd.

Conditions: Age-related Macular Degeneration

Summary: age-related macular degeneration (amd) is a degenerative retinal disease. the prognosis of the exudative form was transformed by the introduction of the anti-vegf monoclonal antibody treatments ranibizumab \[1\] and aflibercept \[2\] in the 2010s. in 2022, a new molecule, faricimab, proved its efficacy in exudative amd. it is a bi-specific monoclonal antibody against vegf-a and ang2. the drug has been granted marketing authorization in france, with reimbursement due to begin in october 2023 for naïve patients as well as for those already treated with ranibizumab or aflibercept. the main advantage of this compound \[3\] is that it extends the injection interval in the treat and extend (t\&e) protocol, which is more extensive than with previous anti-vegf agents. the patients included in the faricimab phase iii study were all naïve to any anti-vegf treatment. in practice, faricimab is likely to offer hope to patients already treated with anti-vegf with a short injection interval to lengthen the number of weeks between injections. as the treatment will be on sale in pharmacies from october 2023, a switch study from previous anti-vegf drugs to faricimab would contribute to an initial real-life evaluation of the drug in this indication.


Eligibility criteria:
inclusion criteria: * male or female patient of legal age (≥18 years) with exudative amd treated with ivt ranibizumab or aflibercept \> 1 year. * patient whose ivt injection interval is strictly less than 12 weeks. exclusion criteria: * severe myopia (axial length \> 26 mm or sphere \< - 6 dioptres). * presence of angioid striae. * presence of moderate or more severe diabetic retinopathy. * history of diabetic macular edema. * history of uveitis. * previous retinal vein occlusion (branch or central vein). * history of pseudovitelliform macular dystrophy. * patient under guardianship or trusteeship * pregnant or breast-feeding woman